Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort

Table 1

Characteristics of the patients in the two groups before and after PSM.

	Before propensity matching			After propensity matching
	NAR; (n = 137)	AR; (n = 139)		NAR; (n = 99)	AR; (n = 99)
Age (year) (n (%))			0.496			0.289
≤60	94 (68.61%)	90 (64.75%)		70 (70.71%)	63 (63.64%)
>60	43 (31.39%)	49 (35.25%)		29 (29.29%)	36 (36.36%)
Sex (n (%))			0.826			0.885
Male	82 (59.85%)	85 (61.15%)		58 (58.59%)	59 (59.60%)
Female	55 (40.15%)	54 (38.85%)		41 (41.41%)	40 (40.40%)
HBV infection (n (%))			0.842			0.605
Yes	36 (26.28%)	38 (27.34%)		20 (20.20%)	23 (23.23%)
No	101 (73.72%)	101 (72.66%)		79 (79.80%)	76 (76.77%)
Smoke history (n (%))			0.731			0.874
Yes	39 (28.47%)	37 (26.62%)		28 (28.28%)	27 (27.27%)
No	98 (71.53%)	102 (73.38%)		71 (71.72%)	72 (72.73%)
Alcohol history (n (%))			0.831			0.849
Yes	25 (18.25%)	24 (17.27%)		17 (17.17%)	16 (16.16%)
No	112 (81.75%)	115 (82.73%)		82 (82.83%)	83 (83.84%)
RBC count (10^12/L)	4.37 ± 0.58	4.24 ± 0.52	0.038	4.35 ± 0.60	4.25 ± 0.51	0.209
HB (g/L)	129.52 ± 19.68	128.11 ± 18.10	0.535	128.59 ± 19.73	127.92 ± 17.94	0.803
ALT (U/L) (n (%))			0.189			0.865
≤40	107 (78.10%)	99 (71.22%)		77 (77.78%)	76 (76.77%)
>40	30 (21.90%)	40 (28.78%)		22 (22.22%)	23 (23.23%)
AST (U/L) (n (%))			0.194			0.736
≤40	106 (77.37%)	98 (70.50%)		77 (77.78%)	75 (75.76%)
>40	31 (22.63%)	41 (29.50%)		22 (22.22%)	24 (24.24%)
ALB (g/L) (n (%))			0.207			0.340
≤35	18 (13.14%)	26 (18.71%)		14 (14.14%)	19 (19.19%)
>35	119 (86.86%)	113 (81.29%)		85 (85.86%)	80 (80.81%)
TB (μmol/L) (n (%))			0.341			0.728
≤20.5	110 (80.29%)	105 (75.54%)		77 (77.78%)	79 (79.80%)
>20.5	27 (19.71%)	34 (24.46%)		22 (22.22%)	20 (20.20%)
BUN (mmol/L)	4.84 ± 1.41	4.85 ± 1.62	0.961	4.82 ± 1.42	4.84 ± 1.54	0.917
CR (μmol/L)	68.30 ± 16.72	68.23 ± 15.83	0.972	68.08 ± 15.16	69.16 ± 16.09	0.627
PT (s)	13.85 ± 1.02	13.75 ± 1.10	0.424	13.90 ± 1.05	13.74 ± 1.08	0.291
PTA (%)	90.37 ± 13.36	92.39 ± 14.57	0.232	89.71 ± 13.64	92.62 ± 14.05	0.141
APTT (s)	37.27 ± 3.57	37.80 ± 4.81	0.302	37.33 ± 3.63	37.67 ± 4.41	0.556
Child–Pugh classification (n (%))			0.046			0.817
A	126 (91.97%)	117 (84.17%)		88 (88.89%)	89 (89.90%)
B	11 (8.03%)	22 (15.83%)		11 (11.11%)	10 (10.10%)
AFP (ng/mL) (n (%))			0.838			0.470
≤40	128 (93.43%)	129 (92.81%)		94 (94.95%)	96 (96.97%)
>40	9 (6.57%)	10 (7.19%)		5 (5.05%)	3 (3.03%)
CA19-9 (U/mL) (n (%))			0.396			0.668
≤37	75 (54.74%)	69 (49.64%)		56 (56.57%)	53 (53.54%)
>37	62 (45.26%)	70 (50.36%)		43 (43.43%)	46 (46.46%)
CEA (ng/mL) (n (%))			0.682			0.579
≤20	127 (92.70%)	127 (91.37%)		91 (91.92%)	93 (93.94%)
>20	10 (7.30%)	12 (8.63%)		8 (8.08%)	6 (6.06%)
Cirrhosis (n (%))			0.508			0.576
Yes	28 (20.44%)	33 (23.74%)		19 (19.19%)	16 (16.16%)
No	109 (79.56%)	106 (76.26%)		80 (80.81%)	83 (83.84%)
Laparoscopic approach (n (%))			0.313			0.712
Yes	27 (19.71%)	21 (15.11%)		19 (19.19%)	17 (17.17%)
No	110 (80.29%)	118 (84.89%)		80 (80.81%)	82 (82.83%)
Robotic approach (n (%))			0.983			0.700
Yes	4 (2.92%)	4 (2.88%)		3 (3.03%)	4 (4.04%)
No	133 (97.08%)	135 (97.12%)		96 (96.97%)	95 (95.96%)
Portal vein occlusion (n (%))			0.054			0.054
Yes	41 (29.93%)	57 (41.01%)		29 (29.29%)	42 (42.42%)
No	96 (70.07%)	82 (58.99%)		70 (70.71%)	57 (57.58%)
IVC occlusion (n (%))			0.813			0.516
Yes	7 (5.11%)	8 (5.76%)		4 (4.04%)	6 (6.06%)
No	130 (94.89%)	131 (94.24%)		95 (95.96%)	93 (93.94%)
Operation time (min)	134.080 ± 112.790	167.990 ± 141.030	0.028	143.420 ± 122.812	165.400 ± 135.210	0.233
Intraoperative hemorrhage (mL)	272.800 ± 257.337	372.900 ± 473.712	0.045	266.230 ± 266.020	375.220 ± 532.383	0.094
Intraoperative transfusion (n (%))			0.023			0.009
Yes	7 (5.11%)	18 (12.95%)		3 (3.03%)	13 (13.13%)
No	130 (94.89%)	121 (87.05%)		96 (96.97%)	86 (86.87%)
Differentiation (n (%))			0.822			0.885
Poor	78 (56.93%)	81 (58.27%)		57 (57.58%)	58 (58.59%)
Well/moderate	59 (43.07%)	58 (41.73%)		42 (42.42%)	41 (41.41%)
Tumor size (cm)			0.225			0.153
≤5	78 (56.93%)	69 (49.64%)		60 (60.61%)	50 (50.51%)
>5	59 (43.07%)	70 (50.36%)		39 (39.39%)	49 (49.49%)
Tumor number			0.001			0.228
Singular	85 (62.04%)	112 (80.58%)		74 (74.75%)	80 (80.81%)
Multiple	52 (37.96%)	27 (19.42%)		25 (25.25%)	19 (19.19%)
Lymph node metastasis			0.006			0.127
Yes	28 (20.44%)	49 (35.25%)		27 (27.27%)	18 (18.18%)
No	109 (79.56%)	90 (64.75%)		72 (72.73%)	81 (81.82%)
Neuron invasion			0.130			0.700
Yes	3 (2.19%)	8 (5.76%)		3 (3.03%)	4 (4.04%)
No	134 (97.81%)	131 (94.24%)		96 (96.97%)	95 (95.96%)
Necrosis			0.419			0.312
Yes	2 (1.46%)	4 (2.88%)		1 (1.01%)	3 (3.03%)
No	135 (98.54%)	135 (97.12%)		98 (98.99%)	96 (96.97%)
PVTT			0.033			0.651
Yes	2 (1.46%)	9 (6.47%)		2 (2.02%)	3 (3.03%)
No	135 (98.54%)	130 (93.53%)		97 (97.98%)	96 (96.97%)
Microvascular invasion			0.393			0.774
Yes	9 (6.57%)	13 (9.35%)		7 (7.07%)	6 (6.06%)
No	128 (93.43%)	126 (90.65%)		92 (92.93%)	93 (93.94%)
Hospital stay (day)	7.61 ± 3.86	10.70 ± 9.29	<0.001	7.85 ± 4.1	10.77 ± 10.03	0.008

HBV: hepatitis B virus, RBC: red blood cell, HB: hemoglobin, ALT: alanine aminotransferase, AST: aspartate transaminase, ALB: albumin, TB: total bilirubin, BUN: blood urea nitrogen, CR: creatinine, PT: prothrombin time, PTA: prothrombin activity, APTT: activated partial thromboplastin time, AFP: alpha-fetoprotein, CA19-9: carbohydrate antigen 19–9, CEA: carcinoembryonic antigen, IVC: inferior vena cava, and PVTT: portal vein tumor thrombosis.